ConcertAI

What ConcertAI does

ConcertAI is an AI-powered SaaS and real-world data company specializing in oncology and other complex diseases, founded in 2017 and headquartered in Cambridge, Massachusetts, operating as a subsidiary of SymphonyAI. The company develops the CARAai platform — a proprietary multi-LLM and agentic AI intelligence layer that extracts oncology variables from unstructured clinical text, powers multi-agent workflows, and grounds outputs against published literature — which underpins its entire product portfolio. Its core offerings span three product lines: (1) the Precision Suite for real-world evidence, including Patient360, Precision360, Translational360, and Precision Explorer, aggregating 13M+ patient records from approximately 1,000 cancer centers integrated with genomic partners Foundation Medicine, Guardant, NeoGenomics, and Caris; (2) Clinical Development solutions including Accelerated Clinical Trials (ACT), an agentic AI platform launched in February 2026 that automates the trial lifecycle, plus TriaLinQ for trial matching; and (3) Commercial Solutions including Cadence Suite, an AI-native application suite for pharmaceutical field teams launched in April 2026. The company also owns the CancerLinQ oncology intelligence network (acquired from ASCO in December 2023), covering 900+ care sites across all 50 states, and TeraRecon, an enterprise imaging platform for MRI/CT visualization and AI biomarker detection acquired via merger in November 2021.

ConcertAI serves two primary customer segments: (a) top-tier life sciences and pharmaceutical companies — it claims 75% of the top 30 life sciences clients and 45+ biopharma partners including AbbVie, AstraZeneca, Eli Lilly, Amgen, Merck, Regeneron, Bayer, and Jazz Pharmaceuticals — and (b) oncology healthcare providers and systems — approximately 50% of the top 250 global healthcare systems, including Mayo Clinic, Duke Health, Penn Medicine, and NHS England. The company monetizes primarily through multi-year enterprise SaaS subscriptions (Clinical Trials, RWE, Commercial, CancerLinQ, TeraRecon), Data-as-a-Service access to its multi-modal oncology datasets, and Professional Services for custom dataset curation, analytics, and regulatory-grade evidence generation. Pricing is custom and quote-based; no public pricing exists. The company maintains a sales-led, enterprise-field-sales go-to-market model with offices in the US, India (Bangalore), Germany (Frankfurt), and Japan (Tokyo).

Recent operating indicators include 1,001–5,000 employees, 500+ peer-reviewed scientific publications using ConcertAI data, 1,900+ global healthcare provider settings where its technologies are deployed, and recognition as a 2026 Fast Company Most Innovative Company and 2026 Frost Radar leader in AI-enabled clinical trials. The company is privately held; its most recent funding round was a $150 million Series C led by Sixth Street in March 2022 at a $1.9 billion post-money valuation.

Name

ConcertAI

Legal name

ConcertAI LLC

Website

https://concertai.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ConcertAI is an AI-powered SaaS and real-world data company specializing in oncology, serving top pharmaceutical companies and major healthcare systems with clinical trial optimization, real-world evidence, and commercial analytics built on its proprietary CARAai multi-LLM platform.

Ownership category

akta.pro rank

Product category

Oncology AI & Real-World Evidence SaaS

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Healthcare AI platform
• Real-world evidence
• Clinical trial optimization
• Oncology data analytics
• AI-powered SaaS

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Enterprise AI SaaS Subscriptions: Subscription-based SaaS solutions for life sciences companies and healthcare providers. Includes clinical trials, real-world evidence, and commercial solutions platforms.
2. Data-as-a-Service (DaaS): Access to proprietary multi-modal oncology datasets including Patient360, Translational360, and Precision360 for evidence generation and research.
3. Clinical Trial Solutions: Enterprise solutions for clinical trial design, site selection, and patient recruitment optimization delivered as SaaS subscriptions.
4. Professional Services: Scientific services including custom dataset curation, analytical services, and consulting for regulatory-grade evidence generation.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

ConcertAI is an AI-powered SaaS and real-world data technology company that builds oncology-focused enterprise platforms combining proprietary multi-modal datasets (13M+ patient records), agentic AI analytics, and clinical workflow tools. Its products enable life sciences companies to optimize clinical trials, generate regulatory-grade real-world evidence, and run commercial pharmaceutical operations, while giving healthcare providers an oncology intelligence network for quality measurement and clinical decision support.

Product overview

ConcertAI is a predictive and generative AI SaaS and real-world data technology company serving life sciences, healthcare, and oncology. The company's offerings follow a platform-plus-modules architecture centered on the CARAai AI intelligence layer. The CARAai platform provides clinical concept extraction, contextual understanding, and multi-source processing capabilities across the portfolio. Key product lines include: Precision Suite (Precision360, Precision Explorer, Translational360, Patient360, Scientific Services) for real-world evidence and regulatory research; Clinical Development solutions including ACT (Accelerated Clinical Trials) and TriaLinQ for clinical trial optimization; Commercial Solutions featuring Cadence Suite and Data Foundry for pharmaceutical commercial teams; CancerLinQ Suite providing oncology provider tools including SmartLinQ with clinical quality, trial matching, and cohort matching; and TeraRecon enterprise imaging solutions including Advanced Visualization (AV, Intuition), DETECT for AI-powered biomarker detection, and AI Framework. The platform integrates multimodal data including EHR, claims, genomic, imaging, and social determinants of health to support evidence generation, clinical trials, and commercial applications across oncology and complex diseases.

Differentiator

Problem solved

Functional benefit

Brands

• CancerLinQ: An initiative of ConcertAI providing oncology providers with ASCO-aligned automated QOPI and ASCO Certified quality solutions and SmartLinQ analytic services. CancerLinQ represents one of the largest oncology real-world data and quality of care technology service entities.
• TeraRecon
• CARAai
• Cadence Suite
• ACT (Accelerated Clinical Trials)

Products and services

• CARAai (Clinical and Research Accelerator) AI platform that serves as the intelligence layer across ConcertAI's product portfolio, extracting key oncology variables (treatment response, metastatic status, stage, ECOG), interpreting implicit and ambiguous clinical references, and processing notes, radiology reports, and labs. Powers multi-LLM and agentic AI capabilities for life sciences and healthcare customers.
• Precision360 Real-world evidence dataset offering weekly AI-curated oncology data from the CancerLinQ network, with comprehensive in-depth coverage for solid and hematologic cancers and access to 13M+ de-identified patient records for life sciences customers.
• Translational360 Clinico-genomic dataset combining clinical and biological data for translational research, integrating DNA mutations, RNA expression, and clinical outcomes within a single framework with 100+ curated clinical variables and 500K combined clinical and biological datasets.
• Patient360 Foundational deeply curated real-world dataset for on-demand evidence generation that integrates EHR, claims, genomic, and social determinants of health data, providing a 360-degree view of the patient journey with 200+ biomarkers and 100+ curated variables from a 13M patient datalake.
• Accelerated Clinical Trials (ACT) Enterprise agentic AI platform built on the CARAai framework that automates and optimizes the full clinical trial lifecycle, leveraging real-world data and predictive analytics to support protocol design, site selection, patient recruitment, and study management for trial sponsors and CROs.
• Cadence Suite AI-native application suite for pharmaceutical commercial and field teams that identifies and resolves patient access barriers (prior authorization delays, coverage confusion, pharmacy stockouts), unifying specialty pharmacy data, claims data, and social determinants of health into a connected view powered by CARA agentic AI.
• CancerLinQ Suite Oncology intelligence platform providing real-world evidence drawn directly from everyday care, with a network of 100+ cancer centers and oncology practices, 10 EMR integrations, and data from nearly 7 million patient records. Includes SmartLinQ SaaS with clinical quality, ASCO-aligned QOPI and ASCO Certified, trial matching, and cohort matching capabilities for oncology providers.
• TeraRecon AV (Advanced Visualization) Advanced medical imaging visualization providing high-performance clinical visualization for MRI and CT, including TeraRecon Intuition for high-performance viewing capabilities, used by radiology departments and enterprise imaging customers.
• TeraRecon DETECT AI-powered biomarker detection tool for clinical and operational workflows in medical imaging, enabling integration of imaging AI into coordinated clinical workflows for radiology and oncology use cases.
• Scientific Services Consultative evidence generation services providing custom datasets, rapid analytics, regulatory-grade evidence generation, and translational insights delivered by a team of epidemiologists, biostatisticians, and data scientists.
• Precision Explorer Real-world data insights platform that generates AI insights from RWD using hallucination-free citations from published literature and comparisons to standards of care, built with the CARA AI engine.
• Data Foundry Data platform providing real-time insights and actionable intelligence for understanding patient journeys in commercial pharmaceutical applications.
• Precision GTM Go-to-market intelligence solution driving engagement and patient access for pharmaceutical commercial teams.

Quantifiable outcome

• Reduces clinical trial timelines by 10-20 months
• +5 more outcomes

Named customers14 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability12 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and major.

• Foundation MedicinecoreStrategic or Co-development Partner · 12 January 2025Collaboration combining Foundation Medicine's genomic testing data with ConcertAI's clinical data to create the largest clinically-linked dataset in the industry, encompassing nearly 500,000 patients for translational research and drug development.
• NeoGenomicscoreStrategic or Co-development Partner · 8 January 2024Collaboration advancing large-scale hematological research solutions combining ConcertAI's longitudinal clinical data with NeoGenomics' comprehensive biomarkers. Dataset covers over one million patient lives across 1,000+ oncology clinics.
• NVIDIAcoreTechnology or IntegrationStrategic collaboration integrating NVIDIA NIM microservices, CUDA-X microservices, and NeMo platform into ConcertAI's suite of AI solutions. Powers scalable, enterprise-ready AI orchestration for clinical development.
• Amazon Web Services (AWS)coreTechnology or IntegrationTechnology partner powering scalable, secure intelligence infrastructure built for healthcare and life sciences demands.
• Guardant HealthcoreStrategic or Co-development PartnerData-sharing partnership to develop multi-modal real-world data solutions for cancer care, combining liquid biopsy and clinical data for comprehensive oncology insights.
• Caris Life SciencescoreTechnology or IntegrationLab partner integrating deep genomic and molecular insights into real-world clinical intelligence through data collaboration.
• BayermajorStrategic or Co-development PartnerMulti-year agreement for AI-powered clinical trial solutions, integrating ConcertAI's ACT platform into Bayer's clinical development programs.
• NeoGenomics (clinical trials)majorStrategic or Co-development PartnerMulti-year agreement for AI-enabled clinical trial optimization and site selection solutions in oncology.
• ASCO (American Society of Clinical Oncology)coreStrategic or Co-development PartnerAcquired CancerLinQ from ASCO in 2023, continuing expansion with ASCO Certified quality framework and ASCO-aligned solutions. ASCO remains a key medical society partner.
• Guardant Health (commercial goals)majorGTM or Marketing PartnerMutual commercial objectives established for the data-sharing deal aimed at advancing cancer therapy commercialization.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Flatiron Health: Roche-owned oncology real-world data and EHR company serving academic centers, community oncology, and life sciences. Direct competitor to ConcertAI's oncology RWE and clinical trial enablement franchises with deep biopharma penetration.
• Tempus AI: AI-powered precision medicine company combining genomic sequencing, real-world data, and AI applications for oncology and other disease areas. Closest direct competitor to ConcertAI on multi-modal oncology data, clinical trial matching, and biopharma RWD.
• Medidata Solutions (Dassault Systèmes): Industry-leading clinical trial technology platform (Rave EDC, CTMS, eCOA) used by most large biopharma sponsors. Direct competitor in clinical trial informatics, with strong overlap to ConcertAI's ACT and TriaLinQ offerings.
• COTA Healthcare: Oncology-focused real-world data and analytics company serving providers, payers, and life sciences. Direct competitor in curated oncology RWE with similar customer segments as ConcertAI's CancerLinQ and Precision360 franchises.
• Syapse: Real-world evidence company focused on oncology, partnering with health systems and life sciences to deliver insights for precision medicine. Direct competitor in oncology RWE and provider data partnerships analogous to CancerLinQ.

Broad incumbents

• IQVIA: Largest life sciences technology and clinical research services provider, with RWE, clinical trial, and commercial analytics franchises. Overlaps with ConcertAI across clinical trial optimization, RWE, and pharma commercial, but operates across all therapeutic areas, not oncology-only.
• Veeva Systems: Cloud software provider for life sciences, including clinical, regulatory, and commercial applications. Overlaps with ConcertAI in clinical trial operations, real-world evidence, and pharma commercial workflows at large biopharma accounts.
• Palantir Technologies: Enterprise data and AI platform with growing footprint in healthcare and life sciences, including clinical trial acceleration and RWE. Overlaps with ConcertAI's data-platform and AI layer (CARAai) and is increasingly competing for biopharma data-infrastructure spend.

Emerging players

• Foundation Medicine: Roche subsidiary providing comprehensive genomic profiling in oncology; both a partner (Foundation Medicine clinico-genomic collaboration, ~500K patients) and adjacent competitor as a source of oncology data feeding into life sciences R&D workflows.
• TriNetX: Global health research network linking providers, biopharma, and CROs for clinical trial design, site selection, and real-world evidence. Comparable to ConcertAI's CancerLinQ/TriaLinQ trial-matching and RWE capabilities, with a broader therapeutic footprint.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ConcertAI
• Facebookfacebook.com/concertai-100655059168014
• LinkedInlinkedin.com/company/concertai

Revenue estimate

Valuation estimate

Number of profiles

Profiles18 records

Subsidiaries2 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ConcertAI